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Abstract 
Oral drug administration remains the preferred approach for treatment of HIV in most patients. 
Maraviroc (MVC) is the first in class co-receptor antagonist, which blocks HIV entry into host 
cells. MVC has an oral bioavailability of approximately 33%, which is limited by poor 
permeability as well as affinity for CYP3A and several drug transporters. While once-daily 
doses are now the favoured option for HIV therapy, dose-limiting postural hypotension has 
been of theoretical concern when administering doses high enough to achieve this for MVC 
(particularly during coadministration of enzyme inhibitors). To overcome low bioavailability and 
modify the pharmacokinetic profile, a series of 70 wt% MVC solid drug nanoparticle (SDN) 
formulations (containing 30wt% of various polymer/surfactant excipients) were generated 
using emulsion templated freeze-drying. The lead formulation contained PVA and AOT 
excipients (MVCSDNPVA/AOT), and was demonstrated to be fully water-dispersible to release drug 
nanoparticles with z-average diameter of 728 nm and polydispersity index of 0.3.  In vitro and 
in vivo studies of MVCSDNPVA/AOT showed increased apparent permeability of MVC, compared 
to a conventional MVC preparation, with in vivo studies in rats showing a 2.5-fold increase in 
AUC (145.33 vs. 58.71 ng.h ml-1). MVC tissue distribution was similar or slightly increased in 
tissues examined compared to the conventional MVC preparation, with the exception of the 
liver, spleen and kidneys, which showed statistically significant increases in MVC for 
MVCSDNPVA/AOT. These data support a novel oral format with the potential for dose reduction 
while maintaining therapeutic MVC exposure and potentially enabling a once-daily fixed dose 
combination product. 
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Introduction 
Oral administration of antiretroviral therapy (ART) has been the standard approach in reducing 
patient mortality [1], and usually involves co-administration of three drugs from at least two 
different classes [2]. Maraviroc (MVC) is an entry inhibitor which targets the CCR5 co-receptor 
to prevent entry of CCR5-tropic virus into T-cells [3]. Oral dosing presents a simple route for 
self-administration but is often limited by low bioavailability. MVC is a class III molecule 
according to the Biophysical Classification System (aqueous solubility = 0.0106 mg/mL, logP 
= 4.37, pKa = 7.3) and a substrate for cytochrome P450 3A (CYP3A) and drug transporters, 
which contribute to its low bioavailability in humans, and up to 60% is estimated to be 
metabolised at first pass [1, 4-8]. In humans, the oral bioavailability of MVC is estimated to be 
approximately 33% for a 300 mg dose, with absolute oral bioavailability of 23.1% at 100 mg 
[9].  
The World Health Organisation (WHO) estimate that over 36 million people were living with 
HIV globally in 2016, with only 19.5 million receiving access to ART. The most affected region 
is Africa which, according to WHO, accounts for approximately two thirds of global new HIV 
infections and 25.6 million people living with HIV. Global efforts are being made to improve 
access to ART, with WHO aiming to increase the number of patients receiving ART from 
approximately 50% to 90% by 2020 [2]. One way in which access to antiretroviral drugs can 
be increased is by reduction in the doses required for viral suppression, which in turn would 
reduce the manufacturing cost of the therapies and improve availability for charitable access 
in less economically developed countries.  
Many drugs may be currently given at higher doses than necessary, which has resulted in 
several recent studies to assess the efficacy of reduced-doses of conventional formulations 
[10-13]. However, nanomedicine approaches offer further opportunities for dose reduction 
while maintaining plasma pharmacokinetic exposure. Indeed, recently we reported an 
emulsion-templated freeze drying (ETFD) approach to prepare solid drug nanoparticles 
(SDNs) for the antiretroviral drugs efavirenz and lopinavir, which resulted in much higher 
plasma concentrations relative to conventional preclinical formulations following oral 
administration [14-16].  
MVC-containing ART regimens require twice-daily administration to patients to maintain 
plasma concentrations within the therapeutic range over the dosing interval. Current dosing 
recommendations for a MVC 300 mg twice-daily dose in adults and adolescents is aimed at 
targeting a median Cavg of 131 ng ml-1, an established parameter relating the MVC efficacy, a 
Cmax of 724.9 ng ml-1 and Cmin between 25 and 50 ng ml-1 depending on the regimen followed 
[3, 17, 18]. Preferred ART regimens currently involve once-daily dosing, but MVC dose has 
not been increased to achieve this due to the theoretical risk of dose-limiting postural 
hypotension, which was seen in clinical development and related predominantly to MVC 
maximum plasma concentrations (Cmax) [19]. MVC efficacy has been associated with average 
plasma concentrations (Cavg) in several studies [16]. Therefore, the aim of this study was to 
develop a MVC SDN formulation with higher bioavailability and lower Cmax:Cavg ratio to support 
dose reduction and once-daily dosing, respectively. Perhaps more importantly, a lower dose 
formulation of MVC may also better support development of MVC-containing fixed dose 
combination (FDC) products. 
The current study reports the development of MVC SDNs generated using ETFD. Polymer 
and surfactant excipients were first studied using a small scale high-throughput screening 
approach to select the most suitable excipients for reproducible scale-up and manufacture. 
Subsequently, SDN lead selection was conducted by screening apparent permeability (Papp) 
across Caco-2 monolayers, before confirmation of improved pharmacokinetic performance 
after oral administration to rats.  
 
  
Experimental 
Materials were purchased and used as received without further purification: α-tocopherol 
poly(ethylene glycol) succinate (TPGS), poly(ethyleneoxide)20 sorbitan monolaurate (Tween 
20), poly(ethyleneoxide)20 sorbitan monooleate (Tween 80), sodium deoxycholate (NDC), 
benzethonium chloride (hyamine), polyvinyl alcohol (PVA), hydroxymethyl propyl cellulose 
(HPMC), poly(ethylene oxide)101-block-poly(propylene oxide)56-block-poly(ethylene 
oxide)101 (Pluronic F127), poly(ethylene oxide)80-block-poly(propylene oxide)27-block-
poly(ethylene oxide)80 (Pluronic F68), sodium 1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-
sulfonate (AOT), Dimethyl sulfoxide (DMSO), acetonitrile, 30% hydrogen peroxide, glacial 
acetic acid, (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), bovine serum 
albumin (BSA), phosphate buffered saline (PBS), Hanks’ balanced salt solution (HBSS) and 
trypsin-EDTA (Sigma–Aldrich, Dorset, UK); poly(ethylene glycol)15-hydroxystearate (Solutol) 
and poly(vinyl alcohol)-graft-poly(ethylene glycol) copolymer (Kollicoat® Protect) (BASF, 
Royal Tunbridge Wells, UK); poly(ethylene glycol) (PEG 1000) and poly(vinylpyrrolidone) 
(PVP K30) (Fluka Chemicals, Dorset, UK); chloroform (Fisher Scientific, Loughbrough, UK); 
MVC was kindly donated by ViiV healthcare (UK) and 3H MVC was purchased from Moravek 
(California, USA). All other chemicals and reagents were purchased from Sigma-Aldrich (UK) 
and used as received, unless stated otherwise. Soluene-350 was purchased from PerkinElmer 
(US). Ultima Gold liquid scintillation fluid was purchased from Meridian biotechnologies (UK) 
and [14C]-mannitol was purchased from American Radiolabelled Chemicals (US). Transwell 
permeable supports with a 0.4 µm pore size were purchased from Corning (US). Caco-2 cells 
were purchased from American Type Culture Collection (ATCC, US).  
 
Emulsion-templated freeze drying of maraviroc SDNs 
Aqueous stock solutions of polymer and surfactants were prepared at 22.5 mg ml-1, MVC was 
prepared was at 70 mg ml-1 in dichloromethane. An example 70 wt% drug loaded SDN was 
prepared as followed: Solutions were prepared at a 4:1 water:oil ratio, with 90 μl polymer, 
45 μl surfactant and 265 μl water added to 100 μl MVC in dichloromethane (DCM). The 
resulting mixture was emulsified with a Covaris S2x for 30 seconds with a duty cycle of 20, 
intensity of 10 and 500 cycles/burst in frequency sweeping mode, after which samples were 
immediately cryogenically frozen. The initial screening consisted of a 49-sample library which 
was prepared as above and lyophilised using a Virtis benchtop K freeze dryer for 48 hours. 
Samples were immediately sealed until analysis. 
 
 
Physical characterisation of MVC SDN library 
Immediately prior to analysis, samples were dispersed in a volume of water to give 1 mg/ml 
with respect to drug concentration. The z-average diameter (nm) of the SDNs was measured 
using dynamic light scattering (DLS; Malvern Zetasizer Nano ZS) using automatic 
measurement optimisation. Zeta potential was also measure with the Malvern Zetasizer Nano 
ZS, using the Smoluchowski model; both DLS and Zeta potential measurements used Malvern 
Zetasizer software version 7.11 for data analysis. Powder X‐ray diffraction (XRD) 
measurements were collected in transmission mode on the solid monolith samples held on a 
thin Mylar film in aluminum well plates on a Panalytical X'Pert PRO MPD instrument with X'Pert 
Operator Interface (version 1.0b) software. 
 
Cell culture and maintenance 
Caco-2 cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented 
with 15% fetal bovine serum (FBS) (Gibco, UK). Cells were incubated at 37oC, 5% CO2. Caco-
2 cells were sub-cultured once ~85% confluent. Cell counting and viability assessments were 
determined using propidium iodide exclusion on a NucleoCounter (Denmark).     
 
Transcellular permeability of maraviroc across Caco-2 monolayers 
Transwells were seeded with 1.5 x 105 cells per well and propagated to a monolayer over 21-
days. During propagation, the media was aspirated from both apical and basolateral 
compartments and replaced with an equal volume of fresh pre-warmed (37oC) media every 
other day, yielding transepithelial electrical resistance (TEER) values of >1000 Ω. After 21-
days, the media was aspirated, wells washed with pre-warmed (37oC) HBSS and replaced 
with either DMSO dissolved MVC (<0.5% DMSO) or MVC nanodispersions, spiked into 
transport buffer, to a final concentration of 10 µM MVC with a specific activity of 25 µCi/mg 
[3H]-MVC. The suspensions were added to either apical or basolateral compartments and 
transport buffer added to the opposing chamber to quantify transport in both apical-to-
basolateral (A>B) and basolateral-to-apical (B>A) directions. One-hundred microliters was 
sampled hourly from the opposing acceptor chamber over 4 h and replaced with an equal 
volume of fresh pre-warmed (37oC) transport buffer. Collected samples were placed into 
empty 5 ml scintillation vials before mixing with liquid scintillation fluid (4 ml). Radioactivity was 
determined as disintegrations per minute (DPM) using a Packard Tri-carb 3100TR liquid 
scintillation counter. Apparent permeability (Papp) was determined by the amount of MVC 
transported over time using equation (1).  
𝑃app =
(d𝑄 d𝑡)⁄ ×  𝑣
𝐴 × 𝐶0
 
            (1) 
Where (dQ/dt) is the amount per time; v is the volume of the receiver compartment; A is the 
surface area of the filter; and C0 is the starting concentration of the donor chamber. Apparent 
oral absorption was calculated using the Papp values: (A>B)/(B>A).   
To assess the integrity of the monolayer following the 4 h incubation, transport buffer was 
aspirated and the wells washed twice with pre-warmed (37oC) HBSS. Subsequently, 0.1 ml of 
transport buffer containing [14C]-mannitol (50 µM, 2 µCi/ml) was added to the apical 
compartment of the test and control wells and 0.55 ml of transport buffer was added to the 
basolateral compartments. The plates were incubated at 37oC, 5% CO2 for 1 h. Following 
incubation, 0.1 ml of the basolateral contents were sampled and placed into empty 5 ml 
scintillation vials before mixing with liquid scintillation fluid (4 ml). Radioactivity was determined 
as described above.  
 
In vivo analysis of lead maraviroc nanodispersion 
All animal work was conducted in accordance with the Animals (Scientific Procedures) Act 
1986 (ASPA) implemented by the UK Home Office. The rodents were housed with 
environmental enrichment and a 12 h light/dark cycle at 21oC ±2oC. Free access to food and 
water was provided at all times. Following 7-days acclimatisation, adult male Wistar rats (280-
330 g) (Charles River, UK) were dosed with 10 mg Kg-1 MVC at 10 µCi/mg, either as a 
conventional [3H]-MVC preparation (<5% DMSO) or as a [3H]-MVCSDNPVA/AOT nanodispersion 
(lead MVC SDN formulation containing PVA and AOT as excipients), using a 7-cm curved 
gavage needle, four rats per condition. Subsequently, blood samples were collected (0.3 ml) 
at 0.5, 1.0, 1.5, 2.0 and 3.0 h post-dosing from the tail vein. At 4.0 h, the rats were sacrificed 
using cardiac puncture under terminal anaesthesia (isoflurane/oxygen), followed by immediate 
exsanguination of blood from the heart. Subsequently, an overdose of sodium pentobarbitone 
(Animalcare, UK) was administered using the same in situ puncture needle. Terminal tissue 
samples were collected, rinsed in PBS and dried on tissue before storing at -20oC. Blood 
samples were collected in heparinised Eppendorf tubes and centrifuged at 3,000 rpm for 
5 min. The plasma layer was collected and stored at -20oC prior to analysis.  
 
Quantification of radiolabelled plasma and tissues 
Plasma samples (0.1 ml) were transferred to scintillation vials before adding scintillation fluid 
(4 ml) (Meridian Biotechnologies, UK) and scintillation counting using a Packard Tri-carb 
3100TR. Each dissected tissue was weighed individually and approximately 100 mg was 
placed into 20 ml scintillation vials. Tissue samples were submerged in 1 ml Soluene-350 
(PerkinElmer, US) and incubated in a water bath at 50oC for 18 h. After allowing to cool to 
room temperature, 0.2 ml of a 30% hydrogen peroxide solution was added to the dissolved 
sample and incubated for 60 min at room temperature. Subsequently, 0.09 ml of glacial acetic 
acid was added to each sample and incubated for a further 15 min at 50oC. Scintillation fluid 
(12 ml) was added to each sample and mixed via inversion. Scintillation counting was carried 
out using a Packard Tri-carb 3100TR. 
 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism v.7 (US). Where statistical analysis 
is described, data normality was assessed with the Shapiro-Wilk test using StatsDirect v.3 
(UK). Data were found to be normally distributed and unpaired, two-tailed t-tests were applied. 
Differences were considered statistically significant at *, P<0.05. Results are expressed as 
means and associated standard deviations. The pharmacokinetic parameters; maximum 
concentration (Cmax), the time to Cmax (Tmax), trough concentrations (Cmin) and the average 
concentration (Cavg) were derived from the concentration-time profiles. The area under the 
curve, (AUC0-4) and half-life (t½) were calculated using PKSolver [20].  
Results and discussion 
Excipient determination by screen 
As described above, MVC SDN library preparation was evaluated against a series of 49 binary 
polymer and surfactant excipients (seven polymers and seven surfactants) selected from the 
U.S. Food and Drug Administration Center for Drug Evaluation and Research list of Inactive 
Ingredients [21]. MVC was dissolved in DCM, and added to an aqueous mixed solution of 
polymer and surfactant to generate a 4:1 ratio of water:oil. This ratio was chosen due to its 
proven success in producing SDNs using the ETFD strategy [15]. The samples were sonicated 
and immediately cryogenically frozen to preserve the emulsion template before freeze drying. 
The rapid cooling generates a thermal shock to the dispersed and continuous phases of the 
emulsion, forcing the phases into a super-saturated regime and generating solid solvent 
regions; where the effective removal of solvent (water or DCM) through crystallisation occurs 
within an amorphous region, this also increases the concentration of the solute in the 
amorphous zones enabling subsequent precipitation or crystallisation of the MVC to occur.  
 
The resulting solid monoliths prepared by ETFD methods were dispersed in water and the 
nanodispersions of MVC were characterised using DLS to determine the z-average diameter 
and polydispersity of the dispersed sample. Samples were evaluated against previously-
established critical criteria to progress to optimisation. Namely, all SDN candidates fully 
dispersed with no residual material, had a z-average diameter <1000 nm, standard deviation 
between each data set <15% and a polydispersity index <0.5. Initially the drug loading relative 
to polymer and surfactant excipient stabilisers was selected as 30 wt%. By applying this 
screening methodology, 9 polymer/surfactant combinations were identified meeting the criteria 
for candidate SDN formulations and subsequent optimisation studies (Fig. 1A).  
 
Optimisation of drug loading  
The initial nine polymer and surfactant combinations found to be successful at 30 wt% were 
adjusted to incorporate higher MVC loadings; this process was deemed to be highly important 
as it establishes the potential for later scale-ability and viable commercial manufacture. In 
each case, the polymer/surfactant combinations were subjected to serial modifications to 
incorporate higher MVC loadings (targeting 70 wt% MVC) at the expense of the stabiliser 
excipient combinations. In general, adjusting the MVC-loading from 40-70 wt% created a 
change in the observed SDN diameter (measured by DLS) (table 1), with no particular trend 
observed; a loose positive correlation between diameter and MVC loading was seen but this 
trend was not clearly established across all SDN candidates, with some maintaining similar 
sizes at all MVC loadings (Fig. 1B). The highest obtainable MVC loading achieved, and hence 
the lowest corresponding polymer and surfactant content, was 70 wt% and three different 
formulations achieved this reproducibly. As seen in previous ETFD studies [14, 15, 22], such 
high drug content is a clear benefit of the ETFD strategy as techniques such as nano-milling 
and high-pressure homogenisation rarely reach drug contents above 30 wt% in their dried and 
re-dispersible form [23]. 
The three solid 70 wt% MVC-loaded SDN formulations which exhibited greatest reproducibility 
all contained the polymer PVA, which has also been found previously to be a successful 
polymer for producing stable SDN candidates from other antiretroviral drugs [14, 15]. The 
surfactants used in the successful SDNs of MVC were tween 80, NDC and AOT. The three 
formulations fully dispersed in water to give particles with diameters spanning 650-850 nm 
(table 2). MVCSDNPVA/AOT exhibited a broader distribution than the other two formulations, 
resulting in a slightly larger polydispersity index. However, because the monolith is known to 
fully disperse upon the addition of water, the particle size distribution was not considered a 
reason to exclude from later pharmacological studies. The zeta potential for the three 
formulations were all negative, with the MVCSDNPVA/TW80 and MVCSDNPVA/NDC having zeta 
potentials closer to neutrality than MVCSDNPVA/AOT, presumably due to the nature of the negative 
charge associated with the AOT surfactant. Analysis of MVCSDNPVA/AOT by XRD shows the 
process of emulsion-templated freeze drying renders the MVC amorphous (fig. S2). Studies 
of a sample stored at room temperature also indicates that the SDN formulation maintains its 
amorphous state even after 20 months of storage. 
 
In vitro permeation studies  
Transwell plates can be used to support Caco-2 monolayers as the cells polarise, differentiate 
and form tight junctions [8]. The polarised monolayer resembles the functional lining of the 
small intestine and therefore offers an in vitro model for absorption across the human gut. The 
apical surface of the cells represents the surface exposed inside the gut while the basolateral 
surface of the cells represents the surface corresponding to the blood. Although not fully 
representative of a materials in vivo behaviour, the model provides exploratory data for further 
development and is widely used to screen drugs for absorption potential [24, 25].  
MVC has previously been shown to have limited apical to basolateral permeation across Caco-
2 monolayers and is a substrate for P-glycoprotein (P-gp) which contributes to enhanced 
basolateral to apical permeation, indicative of transporter-limited absorption [26], usually 
indicative of low oral bioavailability. The three lead SDN formulations, namely MVCSDNPVA/TW80, 
MVCSDNPVA/NDC and MVCSDNPVA/AOT, were prepared at 70 wt% MVC using tritium-labelled MVC 
([3H]-MVC) to enhance the quantitative evaluation of their pharmacological behaviour; 
transcellular permeation of the aqueous SDN nanodispersions was evaluated for both apical 
to basolateral and basolateral to apical permeability and compared to a conventional [3H]-MVC 
preparation (<0.5% aqueous DMSO). The results outlined in Fig. 2 indicate improved apparent 
oral absorption ((Papp(A>B)/Papp(B>A)) of two of the nanodispersed [3H]-MVC formulations 
(MVCSDNPVA/TW80 and MVCSDNPVA/AOT) when compared to a conventional [3H]-MVC preparation; 
>8% and >74% increase after 1 h incubation was observed, respectively. Interestingly, this 
appeared to be largely driven by enhanced apical to basolateral permeation rather than a 
reduction in basolateral to apical permeation (Fig. 2, B). The mechanisms that underpin these 
observations are not clearly understood; however, various processes have been described 
which may account for the observed improvement, including paracellular permeation of intact 
particles, endocytosis of intact particles or indirect mechanisms which enable enhanced 
permeation of the dissolved drug [27]. The paracellular mechanism is characterised by 
permeation of small hydrophilic compounds between adjacent cells [28], although some 
nanoparticles have been shown to reversibly open tight junctions, increasing paracellular 
permeability, to allow larger nanoparticles to permeate across the epithelium and deliver drug-
loaded nanoparticles to the systemic circulation [29]. Endocytosis is an energy-dependant 
transcellular transport mechanism that allows for the internalisation of nanoparticles within 
cells and subsequent transport of intact nanoparticles across the epithelium using membrane-
bound carriers such as endosomes [30, 31]. However, enhanced oral absorption may not rely 
on the permeation of intact nanoparticles and instead, the nanoparticle may enhance drug 
dissolution afforded through supersaturation and increase localised drug concentrations in the 
gut which may ultimately saturate molecular processes and improve drug absorption / oral 
bioavailability [27, 32]. Interestingly, no correlation in the nanosuspensions size (Dz), zeta 
potential (ζ) or polydispersity and [3H]-MVC permeability were identified in the study (data not 
shown).       
The integrity of the Caco-2 monolayers was investigated using the hydrophilic low permeability 
marker [14C]-mannitol following incubation with the conventional and each [3H]-MVC SDN 
candidate. The integrity of the monolayers was assessed post-incubation to determine any 
potential cumulative damage to the monolayer over the 4 h. Co-incubation of each MVC 
preparation and the mannitol marker was not undertaken due to potential interactions of the 
ethanol containing [14C]-mannitol and the MVC nanodispersions. The results outlined in 
Fig. S3 highlight [14C]-mannitol Papp values of less than 0.953 x 10-6 cm s-1 indicating the Caco-
2 monolayers remained intact following exposure to each treatment [25].  
 
Maraviroc in vivo bioavailability studies  
A rat model was used to investigate the in vivo oral pharmacokinetics of [3H]-MVC using the 
aqueous dispersion of the MVCSDNPVA/AOT candidate and a conventional MVC preparation (<5% 
aqueous DMSO). Each treatment group was orally-dosed at 10 mg Kg-1 [3H]-MVC and blood 
samples were collected over 4 h to assess the different pharmacokinetic profiles. The results 
in Fig. 3 A. and Table 3. show increased Cmax (50.74 vs. 26.52 ng ml-1), increased Cmin (25.83 
vs. 8.16 ng ml-1), increased AUC (145.33 vs. 58.71 ng.h ml-1), increased Cavg (38.38 vs. 15.17 
ng ml-1) an equivalent Tmax (time to achieve Cmax after dosing; 1.5 h), reduced Cmax:Cmin ratio 
(1.96 vs. 3.25), reduced Cmax:Cavg ratio (1.32 vs. 1.75) and increased apparent half-life (t½) 
(3.32 vs. 1.57 h) for the MVCSDNPVA/AOT dosed rats compared to the conventional solution in 
aqueous DMSO. The observed improvements in MVC pharmacokinetics could potentially offer 
a number of benefits over conventional therapy. The results presented here highlight an 
increase in AUC and Cmin for MVCSDNPVA/AOT, supporting a dose reduction strategy which 
ensures circulatory MVC concentrations remain efficacious, with an associated lower cost of 
therapy. The reduction in dose also has clear advantages for development of palatable and 
efficacious FDCs. MVC is generally well tolerated but Cmax-driven postural hypotension has 
been described [3, 33], and Cavg is an established parameter relating to efficacy [28]. The 
favourable Cmax:Cavg ratio reported here may enable development of a once-daily format, which 
maintains therapeutic exposure while avoiding the risk of concentration-dependent toxicities.  
Gut metabolism is not believed to contribute significantly to the limited oral bioavailability that 
is observed for MVC in rats. Previous oral dosing studies in rats have shown that only a low 
abundance of metabolites are detectable in the circulating blood and over 79% of the parent 
compound is excreted [3]. It has been suggested that the limited oral bioavailability observed 
for MVC in rats is largely driven by incomplete absorption, which is estimated at 20-30%. In 
the same study, improved MVC oral absorption was noted in dogs and it was suggested that 
this may be due to the larger aqueous pores present in the gastrointestinal tract, aiding MVCs 
absorption  [26, 34]. It is plausible that the nanosuspension enhances MVCs absorption in the 
rat gut leading to the observed improved pharmacokinetic profile. 
In contrast, a mass balance model based on a 300 mg oral dose of MVC in healthy male 
human volunteers indicated that over 80% of the MVC dose was effectively absorbed. The 
same model predicted that the first-pass extraction of MVC is over 60% [9]. It has been 
demonstrated that MVC is predominantly metabolised in the liver by CYP3A with no significant 
involvement of any other CYP450 enzymes [35]. Despite this, unchanged MVC was shown to 
be the major circulating component in plasma (40-42%) and the major excreted component 
(33%) in humans [3, 35]. Interspecies pharmacokinetic scaling is complex [36] and the 
described differences in MVC absorption make the inference of potential pharmacokinetic 
benefits in humans difficult. However, it should be noted that the rats dosed with the MVC 
SDNs appeared to sustain MVC plasma concentrations for longer compared to the 
conventional MVC preparation with an increased Cavg and increased half-life (t½) (3.32 vs. 
1.57 h). The mechanisms underpinning the improvements in the MVC pharmacokinetic profile 
are likely to be complex and multifactorial. One possible explanation for the improvements is 
enhanced MVC lymphatic transport, which would ultimately contribute to the systemic 
exposure and potentially limit first-pass metabolism.  
Lymph tissues are major sanctuary sites for HIV and viral replication occurs in these tissues 
even when the virus is undetectable in circulating blood [37, 38]. Distribution studies using 
intravenously administered [14C]-MVC in rats have shown accumulation of [14C]-MVC in lymph 
nodes both 1 and 4 h post-dose regardless of the lymph node location. Additionally, MVC 
concentrations were shown to be up to seven-fold higher in the lymph nodes than in circulating 
blood [39]. The penetration on MVC into these pharmacologically relevant tissues is likely to 
be important for infection management. A variety of nanoparticle technologies have been 
described with demonstrated or highlighted potential for enhanced lymphatic transport [40-
42]. Microfold cells (M-cells) are a component of the intestinal epithelium that bind, transport 
and deliver macromolecules to the underlying Peyer’s patches which are an organised 
component of the gut-associated lymphoid tissue (GALT) [43]. Enhanced uptake of intact 
nanoparticles or dissolved drug into M-cells potentially allows for effective drug delivery to the 
lymphatics, avoiding first-pass metabolism, and ultimately entering the systemic circulation for 
enhanced drug exposure [44, 45]. Future studies are planned to assess the accumulation of 
antiretrovirals into the lymphatics following oral dosing, using the described nanoparticle 
technology, to ascertain the relevance of this mechanism in drug delivery.        
In addition to the enhanced pharmacokinetics, higher permeation was identified in most of the 
dissected tissues (Fig. 3 B). In particular, statistically significant increases in [3H]-MVC were 
identified in the liver, spleen and kidney with a 2.2 (375.01 vs. 167.84 ng g-1; P=<0.001), 1.6 
(282.68 vs. 167.36 ng g-1; P=<0.001) and 1.8-fold (231.31 vs. 130.47 ng g-1; P=0.0057) 
increase, respectively. All other dissected tissues, except the heart and testis, were also 
shown to have increased MVC concentrations, however these were not considered 
statistically significant. These data must be interpreted in the context that plasma 
concentration was also higher for the SDN. Therefore, a direct comparison was not possible 
and the differences in tissue penetration may be directly related to the difference in plasma 
exposure. This also warrants further study, since the reported approach most likely delivers 
dissolved molecules into the systemic circulation rather than intact nanoparticles.     
Nanoformulations similar to that described here have also attracted recent interest as long-
acting injectables, providing prolonged therapeutic exposure for a period of weeks to months 
from a single intramuscular dose [46]. The lead formulation (MVCSDNPVA/AOT) has also been 
investigated for this route of administration and the data are described elsewhere in this issue 
of the journal [47]. 
 
Conclusions 
The nanomedicine reported here has the potential to enable new MVC dosing formats with 
the potential for once-daily dosing, while reducing doses required for effective viral 
suppression and improving the potential to develop novel ART FDCs. Dose reduction of 
antiretroviral drugs is also considered key to optimising the cost of treatment and improving 
charitable access to therapies for low and middle-income countries. By improving the oral 
bioavailability, the absorption of MVC into systemic circulation was improved, offering a clear 
strategy for reducing the amount of drug required for therapy. In vitro and in vivo studies 
showed improved apparent permeability of the MVCSDNPVA/AOT formulation compared with 
conventional MVC preparations. Studies of tissue distribution revealed significant increases 
of MVC concentration in the spleen, liver and kidney, with distributions into other tissue 
showing slight increases in MVC with the MVCSDNPVA/AOT compared with unformulated MVC. 
These improvements in oral bioavailability show the successful use of the ETFD technology 
to very rapidly identify viable SDN candidates that demonstrate significant benefits to justify 
continued progress towards nanomedicine production. Further study is now required to 
evaluate the implications for drug-interactions with known CYP3A or transporter inhibitors, but 
it may be expected that the magnitude of interaction may be smaller due to the apparent 
change in T½. The most successful, high drug-loaded, water-dispersible SDNs identified 
within this study require further work to translate through to scale-able processes, such as 
spray drying, which are required to establish clinical candidates that have potential for human 
evaluation [14]. 
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Figures 
 
Figure 1: (A) 49 screen of 30 wt% Maraviroc SDNs, containing 30 wt% MVC, 55 wt% Polymer 
and 15 wt% Surfactant. ‘Hits’ highlighted in grey meet the following criteria: Size < 1000 nm, 
PDI < 0.4, Standard deviation < 15% and fully dispersible in water. (B) MVC SDNs 
formulations with increased MVC loadings, measured by DLS. Formulations were prepared 
as follows: 40 wt% MVC, 45 wt% Polymer and 15 wt% Surfactant; 50 wt% MVC, 50 wt% 
Polymer and 10 wt% Surfactant; 60 wt% MVC, 30 wt% Polymer and 10 wt% Surfactant; 70 
wt% MVC, 20 wt% Polymer and 10 wt% Surfactant. 
 
 
 
 
 
 
 
 
Figure 2. (A). Apparent oral absorption (Papp ratio) and (B) apparent permeability (Papp cm s-
1) of a conventional [3H]-MVC preparation (<0.5% DMSO) and three [3H]-MVC 
nanosuspensions across differentiated Caco-2 monolayers following 1 h incubation at 37oC, 
5% CO2. *, P <0.05; **, P <0.01 (unpaired, two-tailed t-test) (n=4).  
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Figure 3. (A). MVC exposure in adult male Wistar rats following oral dosing of [3H]-MVC 
10 mg Kg-1 as a conventional preparation (<5% DMSO) or as a MVC nanodispersion, 
MVCSDNPVA/AOT. The fragmented lines give the standard deviations of the mean for four rats in 
each group. (B). Tissue distribution of [3H]-MVC in adult male Wistar rats following oral dosing 
of [3H]-MVC 10 mg Kg-1 as a conventional preparation (<5% DMSO) or as a MVC 
nanodispersion, MVCSDNPVA/AOT. Data are given as the mean ± standard deviation for four rats 
in each group. **, P <0.01; ***, P <0.001 (unpaired, two-tailed t-test).    
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Table 1. Z-average and PDI of candidates at 30 – 70 wt% loading. 
 
Table 2: Z-average diameter, polydispersity index and zeta potential of the three 70 wt% 
formulations 
Formulation Z-Average /nm Polydispersity Index Zeta Potential /mV 
MVCSDNPVA/TW80 658 0.2 -12.8 
MVCSDNPVA/NDC 823 0.17 -16.6 
MVCSDNPVA/AOT 728 0.3 -25.3 
 
Table 3: Pharmacokinetic parameters derived from Fig. 3 A. 
Pharmacokinetic 
parameter 
Conventional  
MVC 
MVCSDNPVA/AOT P-value (unpaired, 
two-tailed t-test) 
Cmax (ng ml-1) 26.52 50.74 P=0.0190 
Cmin (ng ml-1) 8.16 25.83 P=0.0309 
AUC0-4 (ng.h ml-1) 58.71 145.33 P=0.0028 
Cavg (ng ml-1) 15.17 38.38 P=0.0056 
Tmax (h) 1.5 1.5 - 
Cmax:Cmin ratio 3.25 1.96 P=0.0828 
Cmax:Cavg ratio 1.75 1.32 P=0.0697 
Half-life (t½) (h) 1.57 3.32 P=0.2153 
  
MVC loading 30 wt% 40 wt% 50 wt% 60 wt% 70 wt% 
Polymer Surfactant 
Z-Av 
/nm 
PDI 
Z-Av 
/nm 
PDI 
Z-Av 
/nm 
PDI 
Z-Av 
/nm 
PDI 
Z-Av 
/nm 
PDI 
PVA Tween 20 517 0.30 815 0.60 855 0.38 1247 0.31 950 0.34 
PVA Tween 80 623 0.29 122 0.41 957 0.48 1161 0.26 658 0.20 
PVA NDC 816 0.36 246 0.40 926 0.31 1750 0.31 823 0.17 
PVA AOT 643 0.35 724 0.36 1196 0.36 1205 0.26 728 0.30 
Kollicoat AOT 581 0.27 404 0.47 1124 0.56 1278 0.40 1550 0.71 
PEG1000 AOT 612 0.25 620 0.55 507 0.46 608 0.37 815 0.58 
HPMC AOT 913 0.14 747 0.43 931 0.31 1150 0.45 1824 0.38 
PVP K30 AOT 523 0.35 840 0.84 908 0.58 1951 0.46 3600 0.30 
PVA  Solutol 538 0.34 494 0.39 1193 0.47 1392 0.30 1416 0.35 
 
